Paydirt
NS
Insider

Natarajan Sethuraman

President, Research & Develop.

Natarajan Sethuraman (President, Research & Develop.) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Entrada Therapeutics, Inc. (TRDA). The largest single filing was $399K of TRDA (25,907 sh × $15.39, as filed), executed May 4.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$399K
shares × price, as filed
Last traded
May 4
Filed May 4

Median ADV $2.8M across their filed names

Open performance
Volume by month
$399K$199K$0Oct 2024Apr 2025Oct 2025Apr 2026Nov 2024 · sells $179KDec 2024 · sells $236KMay 2026 · sells $399K
Buys $0 Sells $813K

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names
TRDA Entrada Therapeutics, Inc. TRDA · 0 buys · 3 sells 3 filings
Recent filings
TRDASALE Entrada Therapeutics, Inc. View filing → $399K
25,907 sh × $15.39
Exec May 4
Filed May 4 · 5:30 PM ET
TRDASALE Entrada Therapeutics, Inc. View filing → $236K
11,703 sh × $20.15
Exec Dec 3 2024
Filed Dec 3 2024 · 5:30 PM ET
TRDASALE Entrada Therapeutics, Inc. View filing → $179K
9,554 sh × $18.71
Exec Nov 6 2024
Filed Nov 6 2024 · 5:30 PM ET